Hanall Biopharma Suites Bio-Top Reaches KRW 10 Billion in First Half Sales
Jul 08, 2025
|
Bio-Top is the No. 1 out-of-pocket prescription for four consecutive years since 2021. It grew 37.1% year-on-year last year, recording an annual sales of 17.2 billion won.
The secret to the propaganda of BioTops lies in the differentiation of strains whose efficacy and effectiveness have been verified. Biotap explains that three strains (nacid bacteria, saccharified bacteria, and yeast) included as licensed drugs for direct disease treatment and prevention have been proven to be therapeutic and safe to take through several clinical studies over a long period of time.
Recently, the effect of intestinal health on the whole human body has been actively studied, and interest in probiotics that help keep intestinal microorganisms in balance is also increasing.
The intestines are connected to organs such as the brain, liver, and skin by the Axis, and intestinal microorganisms are transmitted throughout the body through this axis. Therefore, the main goal of the studies is that the balance of microorganisms in the intestine is closely related to the health of each body organ. In particular, short-chain fatty acids produced by butyric acid have been confirmed through several studies for the treatment of metabolic diseases such as diabetes and obesity, inflammatory skin diseases, and dry eyes.
Based on such strain differentiation, Bio-Top has secured a wide range of indications such as ▲ intestinal health improvement ▲ constipation ▲ diarrhea ▲ abdominal distension ▲ intestinal abnormal fermentation, and is gradually expanding its scope in the prescription market.
Prescriptions are increasing not only in diseases such as enteritis and diarrhea that have been mainly prescribed, but also in various combination therapy such as preventing and treating antibiotic-induced diarrhea and using it as an auxiliary treatment for constipation.
Hanall Biopharma plans to secure a continuous success model for major diseases prescribed by BioTop while strengthening scientific clinical evidence through clinical research investments and diversifying its lineup with optimized formulations, ingredients and contents for each major target to continue to grow into blockbuster items.
Park Soo-jin, CEO of Hanall Biopharma, said "BioTop is one of the most prescribed intestinal drugs in the clinical field and is growing into a probiotic brand with a clear basis for efficacy and safety.""In order to provide optimal treatment options for medical staff and patients, we will promote continuous research and development to grow Bio-Top into a luxury brand worth 100 billion won by 2030.""
This article was translated by Naver AI translator.
